Sino Biological Anno...
Influenza Vaccine De...
27th March 2023 Content supplied by: Sino Biological US Inc.
Recombinant Antigens for 2023-2024 Influenza Vaccine Strains
On February 24th, 2023, the World Health Organization (WHO) announced the recommendations for influenza vaccine composition for the 2023-2024 northern hemisphere influenza season. To support vaccine research, Sino Biological has released the recombinant antigens for 2023-2024 influenza vaccine strains.
With the world’s largest viral antigen collection, ProVir®, Sino Biological provides a range of recombinant influenza antigen products, including Hemagglutinin (HA), Neuraminidase (NA), and Nucleoprotein (NP) proteins from all WHO-recommended vaccine strains in recent years. An extensive collection of monoclonal antibodies against the flu antigens are also available to support the development of relevant assays and diagnostic kits.
Visit Sino Biological or click on the Request Information button below.
Tags:
Date Published: 27th March 2023
Source article link: View
Sino Biological Announces Construction of
Influenza Vaccine Development and Production
Address:
Wayne, PA 19087
United States
Tel: +1 215-583-7898
Related news from Sino Biological US Inc.
- Accelerate Mpox Research With Sino Biological MPXV Proteins and Antibodies
- Sino Biological Finalizes the Acquisition of SignalChem Biotech
- Therapeutic Potential of CD20 x CD3 Bispecific Antibodies
- Respiratory Syncytial Virus (RSV) Antigens and Antibodies
- Sino Biological Announces the Opening of Its New US-Based Center for Bioprocessing
- Rapid Antibody Production Services
- Influenza Vaccine Development and Production Solutions
- Sino Biological Announces Construction of Its New US-Based Center for Bioprocessing
- Respiratory Syncytial Virus (RSV) Antigens and Antibodies
- Recombinant Antigens for 2022-2023 Influenza Vaccine Strains
- Sino Biological and Ainnocence Partner to Offer Next-Generation Antibody Development CRO Services
- Sino Biological Invests Over 200M RMB to Establish New Subsidiaries in Taizhou and Suzhou, China.
- Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources
- Sino Biological Establishes New Location in Houston, Texas
- Panel of Research Reagents for SARS-CoV-2 Omicron Variant (B.1.1.529) Launched
- SARS-CoV-2 Omicron Spike Proteins and Antibodies Available
- Sino Biological, Inc. to be Featured on Worldwide Business with kathy ireland®
- 200+ Recombinant SARS-CoV-2 Variants Bank for Vaccine Research
- Sino Biological Announces 4.98 Billion RMB PO and Listing on the Shenzhen ChiNext Stock Exchange
- Variants and Neutralizing Antibodies for SARS-CoV-2